Due to the lack of expression of the molecular targets ER, PGR, and HER2, TNBC has limited therapeutic options, with adjuvant chemotherapy (with regimens of anthracyclines and taxanes used preferably sequentially) as the main recommended treatment option for early, locally advanced, and metastatic BC cases [1,2,3]. Here, ESR1 is linked to breast cancer.